Recombinant Escherichia coli dapA Protein ，His

The study of dapA, which encodes diaminopimelate aminotransferase, has garnered significant attention due to its critical role in bacterial lysine biosynthesis and the peptidoglycan layer formation. This enzyme catalyzes the conversion of L-aspartate-β-semialdehyde to meso-diaminopimelate, an essential intermediate in the lysine biosynthetic pathway, making it a potential target for antibiotic development. Researchers have focused on recombinant dapA protein to better understand its enzyme kinetics, structural characteristics, and catalytic mechanisms. Moreover, given the rising concern over antibiotic resistance, dapA provides a promising avenue for the development of new antimicrobial agents, particularly against Gram-negative pathogens, which often exhibit multidrug resistance. By engineering and characterizing dapA through recombinant DNA technology, scientists aim to elucidate its function, explore its potential as a drug target, and contribute to the design of novel therapeutic strategies. These efforts are integral to addressing public health challenges posed by resistant bacterial strains and enhancing our understanding of basic microbial metabolism. Through structural and functional analyses of the recombinant dapA protein, insights can be gained into its catalytic properties and interactions with inhibitors, paving the way for innovative approaches in antibiotic design aimed at disrupting bacterial growth and survival.